Search

Your search keyword '"Zabaleta A."' showing total 263 results
Start Over Author "Zabaleta A." Publisher american association for cancer research (aacr)
263 results on '"Zabaleta A."'

1. Supplementary Figure S11 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Author

Oliver-Caldes, Aina, primary, Español-Rego, Marta, primary, Zabaleta, Aintzane, primary, González-Calle, Verónica, primary, Navarro-Velázquez, Sergio, primary, Inogés, Susana, primary, de Cerio, Ascensión López-Díaz, primary, Cabañas, Valentín, primary, López-Muñoz, Nieves, primary, Rodríguez-Otero, Paula, primary, Reguera, Juan Luis, primary, Moreno, David F., primary, Martínez-Cibrian, Nuria, primary, López-Corral, Lucía, primary, Pérez-Amill, Lorena, primary, Martin-Antonio, Beatriz, primary, Rosiñol, Laura, primary, Cid, Joan, primary, Tovar, Natalia, primary, Sáez-Peñataro, Joaquín, primary, López-Parra, Miriam, primary, Olesti, Eulalia, primary, Guillén, Elena, primary, Varea, Sara, primary, Rodríguez-Lobato, Luis Gerardo, primary, Battram, Anthony M., primary, González, Marta Sonia, primary, Sánchez-Salinas, Andrés, primary, González-Navarro, Azucena, primary, Ortiz-Maldonado, Valentín, primary, Delgado, Julio, primary, Prósper, Felipe, primary, Juan, Manel, primary, Martínez-López, Joaquín, primary, Moraleda, José M., primary, Mateos, Maria Victoria, primary, Urbano-Ispizua, Álvaro, primary, Paiva, Bruno, primary, Pascal, Mariona, primary, and Fernández de Larrea, Carlos, primary

Published
2024
Full Text
View/download PDF

2. Data from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Author

Oliver-Caldes, Aina, primary, Español-Rego, Marta, primary, Zabaleta, Aintzane, primary, González-Calle, Verónica, primary, Navarro-Velázquez, Sergio, primary, Inogés, Susana, primary, de Cerio, Ascensión López-Díaz, primary, Cabañas, Valentín, primary, López-Muñoz, Nieves, primary, Rodríguez-Otero, Paula, primary, Reguera, Juan Luis, primary, Moreno, David F., primary, Martínez-Cibrian, Nuria, primary, López-Corral, Lucía, primary, Pérez-Amill, Lorena, primary, Martin-Antonio, Beatriz, primary, Rosiñol, Laura, primary, Cid, Joan, primary, Tovar, Natalia, primary, Sáez-Peñataro, Joaquín, primary, López-Parra, Miriam, primary, Olesti, Eulalia, primary, Guillén, Elena, primary, Varea, Sara, primary, Rodríguez-Lobato, Luis Gerardo, primary, Battram, Anthony M., primary, González, Marta Sonia, primary, Sánchez-Salinas, Andrés, primary, González-Navarro, Azucena, primary, Ortiz-Maldonado, Valentín, primary, Delgado, Julio, primary, Prósper, Felipe, primary, Juan, Manel, primary, Martínez-López, Joaquín, primary, Moraleda, José M., primary, Mateos, Maria Victoria, primary, Urbano-Ispizua, Álvaro, primary, Paiva, Bruno, primary, Pascal, Mariona, primary, and Fernández de Larrea, Carlos, primary

Published
2024
Full Text
View/download PDF

3. Supplementary Data S1 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Author

Oliver-Caldes, Aina, primary, Español-Rego, Marta, primary, Zabaleta, Aintzane, primary, González-Calle, Verónica, primary, Navarro-Velázquez, Sergio, primary, Inogés, Susana, primary, de Cerio, Ascensión López-Díaz, primary, Cabañas, Valentín, primary, López-Muñoz, Nieves, primary, Rodríguez-Otero, Paula, primary, Reguera, Juan Luis, primary, Moreno, David F., primary, Martínez-Cibrian, Nuria, primary, López-Corral, Lucía, primary, Pérez-Amill, Lorena, primary, Martin-Antonio, Beatriz, primary, Rosiñol, Laura, primary, Cid, Joan, primary, Tovar, Natalia, primary, Sáez-Peñataro, Joaquín, primary, López-Parra, Miriam, primary, Olesti, Eulalia, primary, Guillén, Elena, primary, Varea, Sara, primary, Rodríguez-Lobato, Luis Gerardo, primary, Battram, Anthony M., primary, González, Marta Sonia, primary, Sánchez-Salinas, Andrés, primary, González-Navarro, Azucena, primary, Ortiz-Maldonado, Valentín, primary, Delgado, Julio, primary, Prósper, Felipe, primary, Juan, Manel, primary, Martínez-López, Joaquín, primary, Moraleda, José M., primary, Mateos, Maria Victoria, primary, Urbano-Ispizua, Álvaro, primary, Paiva, Bruno, primary, Pascal, Mariona, primary, and Fernández de Larrea, Carlos, primary

Published
2024
Full Text
View/download PDF

4. Supplementary Table S8 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Author

Oliver-Caldes, Aina, primary, Español-Rego, Marta, primary, Zabaleta, Aintzane, primary, González-Calle, Verónica, primary, Navarro-Velázquez, Sergio, primary, Inogés, Susana, primary, de Cerio, Ascensión López-Díaz, primary, Cabañas, Valentín, primary, López-Muñoz, Nieves, primary, Rodríguez-Otero, Paula, primary, Reguera, Juan Luis, primary, Moreno, David F., primary, Martínez-Cibrian, Nuria, primary, López-Corral, Lucía, primary, Pérez-Amill, Lorena, primary, Martin-Antonio, Beatriz, primary, Rosiñol, Laura, primary, Cid, Joan, primary, Tovar, Natalia, primary, Sáez-Peñataro, Joaquín, primary, López-Parra, Miriam, primary, Olesti, Eulalia, primary, Guillén, Elena, primary, Varea, Sara, primary, Rodríguez-Lobato, Luis Gerardo, primary, Battram, Anthony M., primary, González, Marta Sonia, primary, Sánchez-Salinas, Andrés, primary, González-Navarro, Azucena, primary, Ortiz-Maldonado, Valentín, primary, Delgado, Julio, primary, Prósper, Felipe, primary, Juan, Manel, primary, Martínez-López, Joaquín, primary, Moraleda, José M., primary, Mateos, Maria Victoria, primary, Urbano-Ispizua, Álvaro, primary, Paiva, Bruno, primary, Pascal, Mariona, primary, and Fernández de Larrea, Carlos, primary

Published
2024
Full Text
View/download PDF

5. Supplementary Methods S1 from Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

Author

Oliver-Caldes, Aina, primary, Español-Rego, Marta, primary, Zabaleta, Aintzane, primary, González-Calle, Verónica, primary, Navarro-Velázquez, Sergio, primary, Inogés, Susana, primary, de Cerio, Ascensión López-Díaz, primary, Cabañas, Valentín, primary, López-Muñoz, Nieves, primary, Rodríguez-Otero, Paula, primary, Reguera, Juan Luis, primary, Moreno, David F., primary, Martínez-Cibrian, Nuria, primary, López-Corral, Lucía, primary, Pérez-Amill, Lorena, primary, Martin-Antonio, Beatriz, primary, Rosiñol, Laura, primary, Cid, Joan, primary, Tovar, Natalia, primary, Sáez-Peñataro, Joaquín, primary, López-Parra, Miriam, primary, Olesti, Eulalia, primary, Guillén, Elena, primary, Varea, Sara, primary, Rodríguez-Lobato, Luis Gerardo, primary, Battram, Anthony M., primary, González, Marta Sonia, primary, Sánchez-Salinas, Andrés, primary, González-Navarro, Azucena, primary, Ortiz-Maldonado, Valentín, primary, Delgado, Julio, primary, Prósper, Felipe, primary, Juan, Manel, primary, Martínez-López, Joaquín, primary, Moraleda, José M., primary, Mateos, Maria Victoria, primary, Urbano-Ispizua, Álvaro, primary, Paiva, Bruno, primary, Pascal, Mariona, primary, and Fernández de Larrea, Carlos, primary

Published
2024
Full Text
View/download PDF

6. Association between Ancestry-Specific 6q25 Variants and Breast Cancer Subtypes in Peruvian Women

Author

Valentina A. Zavala, Sandro Casavilca-Zambrano, Jeannie Navarro-Vásquez, Carlos A. Castañeda, Guillermo Valencia, Zaida Morante, Monica Calderón, Julio E. Abugattas, Henry Gómez, Hugo A. Fuentes, Ruddy Liendo-Picoaga, Jose M. Cotrina, Claudia Monge, Silvia P. Neciosup, Scott Huntsman, Donglei Hu, Sixto E. Sánchez, Michelle A. Williams, Angel Núñez-Marrero, Lenin Godoy, Aaron Hechmer, Adam B. Olshen, Julie Dutil, Elad Ziv, Jovanny Zabaleta, Bizu Gelaye, Jule Vásquez, Marco Gálvez-Nino, Daniel Enriquez-Vera, Tatiana Vidaurre, and Laura Fejerman

Subjects
Receptor, ErbB-2, Epidemiology, Breast Neoplasms, Medical and Health Sciences, Chromosomes, ErbB-2, Receptors, Breast Cancer, Peru, Genetics, 2.1 Biological and endogenous factors, Humans, Aetiology, Progesterone, Cancer, Hispanic or Latino, Estrogen, Good Health and Well Being, Logistic Models, Receptors, Estrogen, Oncology, Chromosomes, Human, Pair 6, Female, Pair 6, Receptors, Progesterone, Human, Receptor
Abstract

Background: Breast cancer incidence in the United States is lower in Hispanic/Latina (H/L) compared with African American/Black or Non-Hispanic White women. An Indigenous American breast cancer–protective germline variant (rs140068132) has been reported near the estrogen receptor 1 gene. This study tests the association of rs140068132 and other polymorphisms in the 6q25 region with subtype-specific breast cancer risk in H/Ls of high Indigenous American ancestry. Methods: Genotypes were obtained for 5,094 Peruvian women with (1,755) and without (3,337) breast cancer. Associations between genotype and overall and subtype-specific risk for the protective variant were tested using logistic regression models and conditional analyses, including other risk-associated polymorphisms in the region. Results: We replicated the reported association between rs140068132 and breast cancer risk overall [odds ratio (OR), 0.53; 95% confidence interval (CI), 0.47–0.59], as well as the lower odds of developing hormone receptor negative (HR−) versus HR+ disease (OR, 0.77; 95% CI, 0.61–0.97). Models, including HER2, showed further heterogeneity with reduced odds for HR+HER2+ (OR, 0.68; 95% CI, 0.51–0.92), HR−HER2+ (OR, 0.63; 95% CI, 0.44–0.90) and HR−HER2− (OR, 0.77; 95% CI, 0.56–1.05) compared with HR+HER2−. Inclusion of other risk-associated variants did not change these observations. Conclusions: The rs140068132 polymorphism is associated with decreased risk of breast cancer in Peruvians and is more protective against HR− and HER2+ diseases independently of other breast cancer-associated variants in the 6q25 region. Impact: These results could inform functional analyses to understand the mechanism by which rs140068132-G reduces risk of breast cancer development in a subtype-specific manner. They also illustrate the importance of including diverse individuals in genetic studies.

Published
2022
Full Text
View/download PDF

8. Abstract 5235: Transcriptome-wide study of tumor samples from Peruvian women identifies dysregulated pathways in luminal tumors typically associated with more aggressive disease

Author

Xu, Chenghuiyun, primary, Zavala-Cordero, Valentina A., additional, Huang, Xiaosong, additional, Rocke, David M., additional, Casavilca-Zambrano, Sandro, additional, Navarro-Vásquez, Jeannie M., additional, Castañeda, Carlos A., additional, Valencia, Guillermo, additional, Morante, Zaida, additional, Calderón, Monica, additional, Abugattas, Julio E., additional, Gómez, Henry, additional, Fuentes, Hugo A., additional, Liendo-Picoaga, Ruddy, additional, Cotrina, Jose M., additional, Neciosup, Silvia P., additional, Roque, Katia, additional, Vásquez, Jule, additional, Mas, Luis, additional, Gálvez-Nino, Marco, additional, Zabaleta, Jovanny, additional, Vidaurre, Tatiana, additional, and Fejerman, Laura, additional

Published
2023
Full Text
View/download PDF

9. Abstract 5237: Regulation of genes located in 6q25 by an Indigenous American genetic variant in breast cancer patients from Peru

Author

Zavala, Valentina A., primary, Huang, Xiaosong, additional, Casavilca-Zambrano, Sandro, additional, Navarro-Vásquez, Jeannie, additional, Castañeda, Carlos A., additional, Valencia, Guillermo, additional, Morante, Zaida, additional, Calderon, Monica, additional, Abugattas, Julio E., additional, Gómez, Henry, additional, Fuentes, Hugo, additional, Liendo-Picoaga, Ruddy, additional, Cotrina, Jose M., additional, Roque, Katia, additional, Vásquez, Jule, additional, Mas, Luis, additional, Gálvez-Nino, Marco, additional, Zabaleta, Jovanny, additional, Vidaurre, Tatiana, additional, and Fejerman, Laura, additional

Published
2023
Full Text
View/download PDF

11. Data from A Recurrent ADPRHL1 Germline Mutation Activates PARP1 and Confers Prostate Cancer Risk in African American Families

Author

Zhang, Guanyi, primary, Wang, Zemin, primary, Bavarva, Jasmin, primary, Kuhns, Katherine J., primary, Guo, Jianhui, primary, Ledet, Elisa M., primary, Qian, Chiping, primary, Lin, Yuan, primary, Fang, Zhide, primary, Zabaleta, Jovanny, primary, Valle, Luis Del, primary, Hu, Jennifer J., primary, Mandal, Diptasri, primary, and Liu, Wanguo, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Table from A Recurrent ADPRHL1 Germline Mutation Activates PARP1 and Confers Prostate Cancer Risk in African American Families

Author

Zhang, Guanyi, primary, Wang, Zemin, primary, Bavarva, Jasmin, primary, Kuhns, Katherine J., primary, Guo, Jianhui, primary, Ledet, Elisa M., primary, Qian, Chiping, primary, Lin, Yuan, primary, Fang, Zhide, primary, Zabaleta, Jovanny, primary, Valle, Luis Del, primary, Hu, Jennifer J., primary, Mandal, Diptasri, primary, and Liu, Wanguo, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Figure from A Recurrent ADPRHL1 Germline Mutation Activates PARP1 and Confers Prostate Cancer Risk in African American Families

Author

Zhang, Guanyi, primary, Wang, Zemin, primary, Bavarva, Jasmin, primary, Kuhns, Katherine J., primary, Guo, Jianhui, primary, Ledet, Elisa M., primary, Qian, Chiping, primary, Lin, Yuan, primary, Fang, Zhide, primary, Zabaleta, Jovanny, primary, Valle, Luis Del, primary, Hu, Jennifer J., primary, Mandal, Diptasri, primary, and Liu, Wanguo, primary

Published
2023
Full Text
View/download PDF

19. Data from Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women

Author

Marker, Katie M., primary, Zavala, Valentina A., primary, Vidaurre, Tatiana, primary, Lott, Paul C., primary, Vásquez, Jeannie Navarro, primary, Casavilca-Zambrano, Sandro, primary, Calderón, Mónica, primary, Abugattas, Julio E., primary, Gómez, Henry L., primary, Fuentes, Hugo A., primary, Picoaga, Ruddy Liendo, primary, Cotrina, Jose M., primary, Neciosup, Silvia P., primary, Castañeda, Carlos A., primary, Morante, Zaida, primary, Valencia, Fernando, primary, Torres, Javier, primary, Echeverry, Magdalena, primary, Bohórquez, Mabel E., primary, Polanco-Echeverry, Guadalupe, primary, Estrada-Florez, Ana P., primary, Serrano-Gómez, Silvia J., primary, Carmona-Valencia, Jenny A., primary, Alvarado-Cabrero, Isabel, primary, Sanabria-Salas, María Carolina, primary, Velez, Alejandro, primary, Donado, Jorge, primary, Song, Sikai, primary, Cherry, Daniel, primary, Tamayo, Lizeth I., primary, Huntsman, Scott, primary, Hu, Donglei, primary, Ruiz-Cordero, Roberto, primary, Balassanian, Ronald, primary, Ziv, Elad, primary, Zabaleta, Jovanny, primary, Carvajal-Carmona, Luis, primary, and Fejerman, Laura, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Figure 3 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Author

Moreno, Laura, primary, Perez, Cristina, primary, Zabaleta, Aintzane, primary, Manrique, Irene, primary, Alignani, Diego, primary, Ajona, Daniel, primary, Blanco, Laura, primary, Lasa, Marta, primary, Maiso, Patricia, primary, Rodriguez, Idoia, primary, Garate, Sonia, primary, Jelinek, Tomas, primary, Segura, Victor, primary, Moreno, Cristina, primary, Merino, Juana, primary, Rodriguez-Otero, Paula, primary, Panizo, Carlos, primary, Prosper, Felipe, primary, San-Miguel, Jesus F., primary, and Paiva, Bruno, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 4 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Author

Moreno, Laura, primary, Perez, Cristina, primary, Zabaleta, Aintzane, primary, Manrique, Irene, primary, Alignani, Diego, primary, Ajona, Daniel, primary, Blanco, Laura, primary, Lasa, Marta, primary, Maiso, Patricia, primary, Rodriguez, Idoia, primary, Garate, Sonia, primary, Jelinek, Tomas, primary, Segura, Victor, primary, Moreno, Cristina, primary, Merino, Juana, primary, Rodriguez-Otero, Paula, primary, Panizo, Carlos, primary, Prosper, Felipe, primary, San-Miguel, Jesus F., primary, and Paiva, Bruno, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 5 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Author

Moreno, Laura, primary, Perez, Cristina, primary, Zabaleta, Aintzane, primary, Manrique, Irene, primary, Alignani, Diego, primary, Ajona, Daniel, primary, Blanco, Laura, primary, Lasa, Marta, primary, Maiso, Patricia, primary, Rodriguez, Idoia, primary, Garate, Sonia, primary, Jelinek, Tomas, primary, Segura, Victor, primary, Moreno, Cristina, primary, Merino, Juana, primary, Rodriguez-Otero, Paula, primary, Panizo, Carlos, primary, Prosper, Felipe, primary, San-Miguel, Jesus F., primary, and Paiva, Bruno, primary

Published
2023
Full Text
View/download PDF

26. Table S1 from Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women

Author

Marker, Katie M., primary, Zavala, Valentina A., primary, Vidaurre, Tatiana, primary, Lott, Paul C., primary, Vásquez, Jeannie Navarro, primary, Casavilca-Zambrano, Sandro, primary, Calderón, Mónica, primary, Abugattas, Julio E., primary, Gómez, Henry L., primary, Fuentes, Hugo A., primary, Picoaga, Ruddy Liendo, primary, Cotrina, Jose M., primary, Neciosup, Silvia P., primary, Castañeda, Carlos A., primary, Morante, Zaida, primary, Valencia, Fernando, primary, Torres, Javier, primary, Echeverry, Magdalena, primary, Bohórquez, Mabel E., primary, Polanco-Echeverry, Guadalupe, primary, Estrada-Florez, Ana P., primary, Serrano-Gómez, Silvia J., primary, Carmona-Valencia, Jenny A., primary, Alvarado-Cabrero, Isabel, primary, Sanabria-Salas, María Carolina, primary, Velez, Alejandro, primary, Donado, Jorge, primary, Song, Sikai, primary, Cherry, Daniel, primary, Tamayo, Lizeth I., primary, Huntsman, Scott, primary, Hu, Donglei, primary, Ruiz-Cordero, Roberto, primary, Balassanian, Ronald, primary, Ziv, Elad, primary, Zabaleta, Jovanny, primary, Carvajal-Carmona, Luis, primary, and Fejerman, Laura, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Figure 1 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Author

Moreno, Laura, primary, Perez, Cristina, primary, Zabaleta, Aintzane, primary, Manrique, Irene, primary, Alignani, Diego, primary, Ajona, Daniel, primary, Blanco, Laura, primary, Lasa, Marta, primary, Maiso, Patricia, primary, Rodriguez, Idoia, primary, Garate, Sonia, primary, Jelinek, Tomas, primary, Segura, Victor, primary, Moreno, Cristina, primary, Merino, Juana, primary, Rodriguez-Otero, Paula, primary, Panizo, Carlos, primary, Prosper, Felipe, primary, San-Miguel, Jesus F., primary, and Paiva, Bruno, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Figure 2 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Author

Moreno, Laura, primary, Perez, Cristina, primary, Zabaleta, Aintzane, primary, Manrique, Irene, primary, Alignani, Diego, primary, Ajona, Daniel, primary, Blanco, Laura, primary, Lasa, Marta, primary, Maiso, Patricia, primary, Rodriguez, Idoia, primary, Garate, Sonia, primary, Jelinek, Tomas, primary, Segura, Victor, primary, Moreno, Cristina, primary, Merino, Juana, primary, Rodriguez-Otero, Paula, primary, Panizo, Carlos, primary, Prosper, Felipe, primary, San-Miguel, Jesus F., primary, and Paiva, Bruno, primary

Published
2023
Full Text
View/download PDF

33. Supplementary Information from Arginase-Producing Myeloid Suppressor Cells in Renal Cell Carcinoma Patients: A Mechanism of Tumor Evasion

Author

Zea, Arnold H., primary, Rodriguez, Paulo C., primary, Atkins, Michael B., primary, Hernandez, Claudia, primary, Signoretti, Sabina, primary, Zabaleta, Jovanny, primary, McDermott, David, primary, Quiceno, David, primary, Youmans, Amanda, primary, O'Neill, Anne, primary, Mier, James, primary, and Ochoa, Augusto C., primary

Published
2023
Full Text
View/download PDF

38. Abstract P6-01-40: Integrative transcriptomic analysis and cohort validation identify key genes in chemotherapy treatment response in Latino breast cancer patients

Author

Guevara-Nieto, Hedda Michelle, primary, Parra-Medina, Rafael, additional, Mejia-Henao, Juan C., additional, López-Correa, Patricia, additional, Diaz, Sandra, additional, Garai, Jone, additional, Zabaleta, Jovanny, additional, López-Kleine, Liliana, additional, and Combita, Alba L., additional

Published
2023
Full Text
View/download PDF

39. Data from A Recurrent ADPRHL1 Germline Mutation Activates PARP1 and Confers Prostate Cancer Risk in African American Families

Author

Wanguo Liu, Diptasri Mandal, Jennifer J. Hu, Luis Del Valle, Jovanny Zabaleta, Zhide Fang, Yuan Lin, Chiping Qian, Elisa M. Ledet, Jianhui Guo, Katherine J. Kuhns, Jasmin Bavarva, Zemin Wang, and Guanyi Zhang

Abstract

African American (AA) families have the highest risk of prostate cancer. However, the genetic factors contributing to prostate cancer susceptibility in AA families remain poorly understood. We performed whole-exome sequencing of one affected and one unaffected brother in an AA family with hereditary prostate cancer. The novel non-synonymous variants discovered only in the affected individuals were further analyzed in all affected and unaffected men in 20 AA-PC families. Here, we report one rare recurrent ADPRHL1 germline mutation (c.A233T; p.D78V) in four of the 20 families affected by prostate cancer. The mutation co-segregates with prostate cancer in two families and presents in two affected men in the other two families, but was absent in 170 unrelated healthy AA men. Functional characterization of the mutation in benign prostate cells showed aberrant promotion of cell proliferation, whereas expression of the wild-type ADPRHL1 in prostate cancer cells suppressed cell proliferation and oncogenesis. Mechanistically, the ADPRHL1 mutant activates PARP1, leading to an increased H2O2 or cisplatin-induced DNA damage response for prostate cancer cell survival. Indeed, the PARP1 inhibitor, olaparib, suppresses prostate cancer cell survival induced by mutant ADPRHL1. Given that the expression levels of ADPRHL1 are significantly high in normal prostate tissues and reduce stepwise as Gleason scores increase in tumors, our findings provide genetic, biochemical, and clinicopathological evidence that ADPRHL1 is a tumor suppressor in prostate tissue. A loss of function mutation in ADPRHL1 induces prostate tumorigenesis and confers prostate cancer susceptibility in high-risk AA families.Implications:This study highlights a potential strategy for ADPRHL1 mutation detection in prostate cancer–risk assessment and a potential therapeutic application for individuals with prostate cancer in AA families.

Published
2023
Full Text
View/download PDF

42. Supplementary Figure from A Recurrent ADPRHL1 Germline Mutation Activates PARP1 and Confers Prostate Cancer Risk in African American Families

Author

Wanguo Liu, Diptasri Mandal, Jennifer J. Hu, Luis Del Valle, Jovanny Zabaleta, Zhide Fang, Yuan Lin, Chiping Qian, Elisa M. Ledet, Jianhui Guo, Katherine J. Kuhns, Jasmin Bavarva, Zemin Wang, and Guanyi Zhang

Abstract

Supplementary Figure from A Recurrent ADPRHL1 Germline Mutation Activates PARP1 and Confers Prostate Cancer Risk in African American Families

Published
2023
Full Text
View/download PDF

45. Supplementary Table from A Recurrent ADPRHL1 Germline Mutation Activates PARP1 and Confers Prostate Cancer Risk in African American Families

Author

Wanguo Liu, Diptasri Mandal, Jennifer J. Hu, Luis Del Valle, Jovanny Zabaleta, Zhide Fang, Yuan Lin, Chiping Qian, Elisa M. Ledet, Jianhui Guo, Katherine J. Kuhns, Jasmin Bavarva, Zemin Wang, and Guanyi Zhang

Abstract

Supplementary Table from A Recurrent ADPRHL1 Germline Mutation Activates PARP1 and Confers Prostate Cancer Risk in African American Families

Published
2023
Full Text
View/download PDF

47. Data from Cross-talk between 4-1BB and TLR1–TLR2 Signaling in CD8+ T Cells Regulates TLR2′s Costimulatory Effects

Author

Eduardo Davila, Jovanny Zabaleta, Ratika Srivastava, and Ann Mary Joseph

Abstract

The activation of TLR-MyD88 (Toll-like receptor-myeloid differentiation factor 88) signaling within T cells functions as a potent costimulatory signal that boosts antitumor and antiviral responses. However, the molecular mechanisms underlying the costimulatory processes are poorly understood. We compared microarray gene analysis data between TLR1–TLR2-stimulated and unstimulated T-cell receptor transgenic “pmel” and MyD88−/− pmel CD8+ T cells and identified changes in the expression of several TNF family members. In particular, TLR stimulation increased 4-1BB levels in pmel but not in MyD88−/−pmel T cells. A link between 4-1BB and TLR1–TLR2 signaling in CD8+ T cells was highlighted by the suboptimal responses of 4-1BB−/− T cells to TLR1–TLR2 agonist, but their normal response to CD28 or OX40 costimulation. Blocking 4-1BB signaling with antibodies also hindered the costimulatory effects of the TLR1–TLR2 agonist. The elevated levels of 4-1BB transcripts in TLR1–TLR2-stimulated cells were not due to increased mRNA stability nor increased histone activation, but instead were associated with increased binding of p65 and c-Jun to two distinct 4-1BB promoter sites. Combining TLR1–TLR2 ligand with an agonistic antibody to 4-1BB enhanced the antitumor activity in mice with established melanoma tumors. These studies reveal that the costimulatory effects of TLR1–TLR2 signaling in CD8+ T cells are in part mediated by 4-1BB and are important for mounting an effective antitumor immune response. Cancer Immunol Res; 4(8); 708–16. ©2016 AACR.

Published
2023
Full Text
View/download PDF

48. Table S2 from Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer Is Associated with Indigenous American Ancestry in Latin American Women

Author

Laura Fejerman, Luis Carvajal-Carmona, Jovanny Zabaleta, Elad Ziv, Ronald Balassanian, Roberto Ruiz-Cordero, Donglei Hu, Scott Huntsman, Lizeth I. Tamayo, Daniel Cherry, Sikai Song, Jorge Donado, Alejandro Velez, María Carolina Sanabria-Salas, Isabel Alvarado-Cabrero, Jenny A. Carmona-Valencia, Silvia J. Serrano-Gómez, Ana P. Estrada-Florez, Guadalupe Polanco-Echeverry, Mabel E. Bohórquez, Magdalena Echeverry, Javier Torres, Fernando Valencia, Zaida Morante, Carlos A. Castañeda, Silvia P. Neciosup, Jose M. Cotrina, Ruddy Liendo Picoaga, Hugo A. Fuentes, Henry L. Gómez, Julio E. Abugattas, Mónica Calderón, Sandro Casavilca-Zambrano, Jeannie Navarro Vásquez, Paul C. Lott, Tatiana Vidaurre, Valentina A. Zavala, and Katie M. Marker

Abstract

Association between ER/PR/HER2 defined groups and Indigenous American genetic ancestry including stage and region of residence as covariates

Published
2023
Full Text
View/download PDF

49. Data from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Author

Bruno Paiva, Jesus F. San-Miguel, Felipe Prosper, Carlos Panizo, Paula Rodriguez-Otero, Juana Merino, Cristina Moreno, Victor Segura, Tomas Jelinek, Sonia Garate, Idoia Rodriguez, Patricia Maiso, Marta Lasa, Laura Blanco, Daniel Ajona, Diego Alignani, Irene Manrique, Aintzane Zabaleta, Cristina Perez, and Laura Moreno

Abstract

Purpose:Knowledge about the mechanism of action (MoA) of monoclonal antibodies (mAb) is required to understand which patients with multiple myeloma (MM) benefit the most from a given mAb, alone or in combination therapy. Although there is considerable research about daratumumab, knowledge about other anti-CD38 mAbs remains scarce.Experimental Design:We performed a comprehensive analysis of the MoA of isatuximab.Results:Isatuximab induces internalization of CD38 but not its significant release from MM cell surface. In addition, we uncovered an association between levels of CD38 expression and different MoA: (i) Isatuximab was unable to induce direct apoptosis on MM cells with CD38 levels closer to those in patients with MM, (ii) isatuximab sensitized CD38hi MM cells to bortezomib plus dexamethasone in the presence of stroma, (iii) antibody-dependent cellular cytotoxicity (ADCC) was triggered by CD38lo and CD38hi tumor plasma cells (PC), (iv) antibody-dependent cellular phagocytosis (ADCP) was triggered only by CD38hi MM cells, whereas (v) complement-dependent cytotoxicity could be triggered in less than half of the patient samples (those with elevated levels of CD38). Furthermore, we showed that isatuximab depletes CD38hi B-lymphocyte precursors and natural killer (NK) lymphocytes ex vivo—the latter through activation followed by exhaustion and eventually phagocytosis.Conclusions:This study provides a framework to understand response determinants in patients treated with isatuximab based on the number of MoA triggered by CD38 levels of expression, and for the design of effective combinations aimed at capitalizing disrupted tumor–stroma cell protection, augmenting NK lymphocyte–mediated ADCC, or facilitating ADCP in CD38lo MM patients.See related commentary by Malavasi and Faini, p. 2946

Published
2023
Full Text
View/download PDF

50. Supplementary Figure 2 from The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma

Author

Bruno Paiva, Jesus F. San-Miguel, Felipe Prosper, Carlos Panizo, Paula Rodriguez-Otero, Juana Merino, Cristina Moreno, Victor Segura, Tomas Jelinek, Sonia Garate, Idoia Rodriguez, Patricia Maiso, Marta Lasa, Laura Blanco, Daniel Ajona, Diego Alignani, Irene Manrique, Aintzane Zabaleta, Cristina Perez, and Laura Moreno

Abstract

Supplementary Figure 2

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results